{"schema_version":"secwatch.filing_event.v1","accession":"0001448431-25-000018","form_type":"8-K","ticker":"OPRX","cik":"0001448431","company_name":"OptimizeRx Corp","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.432267+00:00","generated_at":"2026-05-16T23:35:34.399068+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"OptimizeRx posts Q3 net income of $0.8M, revenue up 22% to $26.1M; raises FY2025 outlook","bullets":["Q3 revenue $26.1M (+22% YoY); GAAP net income $0.8M ($0.04/share) vs loss of $9.1M in Q3 2024.","Adjusted EBITDA $5.1M (up from $2.7M); gross profit $17.5M (+30% YoY).","Raised FY2025 guidance: revenue $105-109M, adjusted EBITDA $16-19M.","Introduced FY2026 guidance: revenue $118-124M, adjusted EBITDA $19-22M.","Cash $19.5M at Sep 30, 2025; paid $2M on term loan post-quarter."],"urls":{"canonical":"https://secwatch.observer/filing/0001448431-25-000018","json":"https://secwatch.observer/filing/0001448431-25-000018.json","markdown":"https://secwatch.observer/filing/0001448431-25-000018.md","text":"https://secwatch.observer/filing/0001448431-25-000018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1448431/000144843125000018/0001448431-25-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1448431/000144843125000018/oprx-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:35:34.399068+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}